Traditional, unfairly forgotten, rarely used and promising drug delivery methods in ophthalmology: a clinical interpretation (part 1)
https://doi.org/10.21516/2072-0076-2019-12-2-83-95
Abstract
Ocular targeted drug delivery is one of the most challenging tasks for pharmaceutical researchers and practical ophthalmologists. The possibilities of drug delivery to the eye are naturally determined by the anatomical structure of the eye and its physiological properties, which restrict the period when therapeutically required drug concentration could be maintained. Combined drug delivery schemes may, potentially, improve the patient’s acceptance of treatment, reduce side effects, increase efficacy, and eventually preserve vision.
About the Authors
A. V. Kuroyedov
P.V. Mandryka Military Clinical Hospital; N.I. Pirogov National Medical University
Russian Federation
Russian Federation
Dr. Med. Sci., Professor, head of ophthalmological department1, chair of ophthalmology
8a, Bolshaya Olenya St., Moscow, 107014
1, Ostrovityanova St., Moscow, 117997
V. V. Brzhesky
State Pediatric Medical University
Russian Federation
Russian Federation
Dr. Med. Sci., Professor, head of chair of ophthalmology
2, Litovskaya St., St. Petersburg, 194100
E. A. Krinitsyna
N.I. Pirogov National Medical University
Russian Federation
Russian Federation
resident
1, Ostrovityanova St., Moscow, 117997
References
1. Krasnov M.L., Shul'pina N.B. Therapeutic ophthalmology. Moscow: Meditsina; 1985 (in Russian).
2. Krasnov M.M., Arnautova L.G. A new method of retrograde intraarterial administration of medicinal agents in a. ophthalmica in the treatment of eye diseases. Vestnik oftal’mologii. 1976; 6: 46–50 (in Russian).
3. Thassu D., Deleers M., Pathak Y., eds. Nanoparticulate Drug Delivery Systems. 1st Edition. New York: CRC Press; 2007.
4. Egorov E.A. Rational pharmacotherapy in ophthalmology. Moscow: Littera; 2004 (in Russian).
5. Bourlais C.L., Acar L., Zia H., et al. Ophthalmic drug delivery systems — recent advances. Prog. Retin. Eye. Res. 1998; 17 (1): 33–58.
6. Davies N.M., Farr S.J., Hadgraft J., et al. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res. 1991; 8 (8): 1039–43.
7. Cuncha-Vaz J.G. The blood-ocular barriers: past, present and future. Doc. Ophthalmol. 1997; 93 (1–2): 149–57.
8. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006; 58 (11): 1131–5.
9. Hoffman A.S. The origins and evolution of «controlled» drug delivery systems. J. Control Release. 2008; 132 (3): 153–63. doi: 10.1016/j.jconrel.2008.08.012
10. Nesterov A.P., Egorov E.A., Egorov A.E., et al. A new way of administration of medicinal agents in diseases of the posterior segment of the eye and its use for the treatment of glaucoma optic neuropathy. Klinicheskaja Oftal’mologija. 2000; 2 (1): 39–41 (in Russian).
11. Tangri P., Khuhara S. Basic of ocular drug delivery systems: review. Int. J. Res. Pharmaceutical Biomedical Sci. 2011; 2 (4): 1541–52.
12. Lavik E., Kuehn M.H., Kwon Y.H. Novel drug delivery systems for glaucoma. Eye. 2011; 25 (5): 578–86. doi: 10.1038/eye.2011.82
13. Khaleeva E.L., Pertsev I.M., Tikhonova S.A., Piminov A.F. Eye medicinal preparations. Medical and Biological and Pharmaceutical Aspects: a Handbook. Kharkiv: NFaU; 2006 (in Russian).
14. Kuno N., Fujii S. Recent advances in ocular drug delivery system. Polymers. 2011; 3 (1): 193–221. Available at: https://doi.org/10.3390/polym3010193
15. Vokhmyakov A.V. Evolution of tear substitutes: from salt solutions to cationic nanoemulsions. Oftal’mologicheskij zhurnal. 2014; 7 (1): 41–6 (in Russian).
16. Cursiefen C., Viaud E., Bock F., et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. Ophthalmology. 2014; 121 (9): 1683–92. doi:10.1016/j.ophtha.2014.03.038
17. Fiscella R.G., Wilensky J.T., Chiang T.H., et al. Efficiency of instillation methods for prostaglandin medications. J. Ocul. Pharm. Ther. 2006; 22 (6): 477–82. doi: 10.1089/jop.2006.22.477
18. Ivashina A.I., Pivovarov N.N., Agafonova V.V., et al. Prelimbal anesthesia. Ophthalmic Surgery. 1998; 4: 44–8 (in Russian).
19. Volkov V.V., Brzheskii V.V., Gladkikh A.F. Diagnosis and treatment of the syndrome of “dry eyes” burned etiology. Oftal’mologicheskij zhurnal. 1990; 6: 328–30 (in Russian).
20. Brzheskii V.V. Tactics of medicamental treatment of patients with various clinical forms of dry eye syndrome. RMJ. Klinicheskaja oftal’mologija. 2008; 9 (1): 4–7 (in Russian).
21. Maychuk Yu.F. New in epidemiology and pharmacotherapy of eye infections. Klinicheskaja oftal’mologija. 2000; 1 (2): 48–5 (in Russian).
22. Inozemtseva N.V., Kondrat'eva T.S. Drops for the treatment of inflammatory eye diseases. Patent RF № 2149611; 2000 (in Russian).
23. Malyugin B.E., Timoshkina N.T., Bagrov S.N., et al. Method of anaesthesia in ophthalmology. Patent RF № 2161464; 2001 (in Russian).
24. Rouland J.F., Morel-Mandrino P., Elena P.P., Polzer H., Sunder Raj P. Timolol 0.1 % gel (Nyogel 0.1 % once daily versus conventional timolol 0.5 % solution twice daily: a comparison of efficacy and safety. Ophthalmologica. 2002; 216 (6): 449–54. doi: 10.1159/000067548
25. Yulitalo R.V., Iokinen A.E., Muratova N.V. Efficacy, tolerability and compliance of «Oftagel» treatment in patients with dry eye syndrome. RMJ. Klinicheskaja oftal’mologija. 2002; 3 (4): 179–83 (in Russian).
26. Chekina A.Yu., Marchenko L.N., Birich T.A., et al. The effectiveness of ganciclovir 0.15 % (Virgan) in comparison with the known antimetabolites used in the treatment of herpetic keratitis. ARS-Medica. 2010; 13: 151–6 (in Russian).
27. Vakhova E.S., Maychuk Yu.F. Actual therapy of chlamydia conjunctivitis. Refraction Surgery and Ophthalmology. 2009; 2: 43–8 (in Russian).
28. Volkov V.V., Krasnov A.M., Khromov G.L. Application of eye medicinal films in the field conditions. Voenno-meditsinskij zhurnal. 1978; 2: 43–6 (in Russian).
29. Maychuk Yu.F. Viral eye diseases. Мoscow: Meditsina; 1981(in Russian).
30. Maychuk Yu.F. Pharmaceutical and clinical assessment of soluble ocular films with pilocarpine. Vestnik oftal’mologii. 1981; 2: 48–9 (in Russian).
31. Egorov E.A., Katz D.V., Shvets N.N. Prolonged neuroprotection of GON. Klinicheskaja oftal’mologija. 2008; 2 (9): 49–51 (in Russian).
32. Maychuk Yu.F., Khromov G.L. About the eye medicinal films with kanamycin. Vestnik oftal’mologii. 1977; 6: 61–2 (in Russian).
33. Boiko E.V., Danilichev V.F., Reituzov V.A., et al. A possibility of application of soft contact lenses saturated with antibiotics for perioperative prevention of intraocular infections. Oftal’mologicheskie vedomosti. 2008; 1 (1): 18–23 (in Russian).
34. Zelenskaya M.V. Therapeutic contact lenses. Glaz. 1998; 3: 36–7 (in Russian).
35. Rybakova E.G., Egorova G.B. The use of contact lenses in the treatment of corneal diseases. Klinicheskaja oftal’mologija. 2000; 4: 111–3 (in Russian).
36. Aleksandrova Zh.L. The use of soft contact lenses for therapeutic purposes in children. St. Petersburg; 2006 (in Russian).
37. Danilichev V.F., Novikov S.A., Ushakov N.A., et al. Contact lenses. St. Petersburg: RA Veko; 2008 (in Russian).
38. Fokina D.V., Reytuzov V.A., Kirillov Yu.A. Rationale for the use of ionic soft contact lenses, saturated with fluoroquinolones of the latest generation, in order to prevent intraocular infection. Sovremennaja optometrija. 2011; 6: 34–8 (in Russian).
39. Fokina D.V., Reytuzov V.A., Kirillov Yu.A. Comparison of the effectiveness of ionic soft contact lenses saturated with 5-fluoroquinolones for the prevention of intraocular infection in open eye injury. Medical-biological and sociopsychological problems of safety in emergency situations. 2011; 3: 42–6 (in Russian).
40. Ciolino J.B., Hudson S.P., Mobbs A.N., et al. A prototype antifungal contact lens. Invest. Ophthalmol. Vis. Sci. 2011; 52 (9): 6286-91. doi: 10.1167/iovs.10-6935
41. Avetisov E.S., Rybakova E.G. Contact lenses in ophthalmopediatrics. Glaz. 1998; 2: 38–41 (in Russian).
42. Pavlyuchenko V.N., Ushakov N.A., Novikov S.A., et al. Polymer hydrogels based on 2-hydroxyethylmethacrylate: modification, sorption and desorption of aminoglycosides. Journal of Applied Chemistry. 2006. 79 (4): 593–8 (in Russian).
43. Hehl E.M., Beck R., Luthard K., et al. Improved penetration of aminoglycosides and fluoroquinolones into the aqueous humour of patients by means of Acuvue contact lenses. Eur. J. Clin. Pharmacol. 1999; 55 (4): 317–23.
44. Zhilyakova E.T., Novikov O.O., Akopova V.V., et al. Study of the surface and the structure of soft contact lenses for the development of eye tissues therapeutic ophthalmic drug delivery system. Nauchnye vedomosti. 2010; 22: 73–6 (in Russian).
45. Ushakov N.A., Gudakovsky Yu.P., Gladkih A.F. On the application of soft contact lenses in injuries and diseases of the eye. Voenno-Meditsinskij zhurnal. 1992; 8: 54–5 (in Russian).
46. Ushakov N.A., Novikov S.A., Muravyeva E.V., et al. In: Danilichev V.F., ed. Therapeutic and corrective contact lenses. Modern ophthalmology: a manual for physicians. Sankt-Petersburg: Piter; 2000 (in Russian).
47. Novikov S.A., Koltsov A.A., Reytuzov V.A. Therapeutic soft contact lenses: classification, indications for use and prospects. Sovremennaja optometrija. 2013; 3: 9–15 (in Russian).
48. Akopova V.V., Zhilyakova E.T., Blagorazumnaya N.V. The study the processes of sorption and desorption of Miramistin in the ophthalmic therapeutic system. Scientific statements of BelSU. Series “Medicine. Pharmacy”. 2011; 22: 114–6 (in Russian).
49. Gulsen D., Chauhan A. Ophthalmic drug delivery through contact lenses. Invest. Ophthalmol. Vis. Sci. 2004; 45 (7): 2342–7.
50. Ciolino J.B., Hoare T.R., Iwata N.G., et al. A drug-eluting contact lens. Invest. Ophthalmol. Vis. Sci. 2009; 50 (7): 3346–52. doi: 10.1167/iovs.08-2826
51. Ciolino J.B., Hudson S.P., Mobbs A.N., et al. A prototype antifungal contact lens. Invest. Ophthalmol. Vis. Sci. 2011; 52 (9): 6286–91. doi: 10.1167/iovs.10-6935
52. Polymer eye films. Available at: https://studfiles.net/preview/5871894/page:6/
53. Ivanova L.A., Sychenikov I.A., Kondratyeva T.S. Collagen in medicine technology. Moscow: Meditsina; 1984 (in Russian).
54. Nuritdinov V.A. Luminescent analysis of tetracycline in the anterior chamber of the eye. Vestnik oftal’mologii. 1979; 1: 49–50 (in Russian).
55. Boiko E.V., Danilichev V.F., Sazhin T.G. Enzymotherapy of fibrinoid syndrome after phacoemulsification. Oftal’mokhirurgija. 2005; 3: 25–9 (in Russian).
56. Mishchenko N.P., Fedoreev S.A., Dogadova L.P. The drug histochrome for ophthalmology. Vestnik DVO RAN. 2004; 3: 111–9 (in Russian).
57. Egorov E.A., Alekhina V.A., Volobueva T.M., et al. New bioantioxidant histochrome in the clinic of eye diseases. Vestnik oftal’mologii. 1999; 115 (2): 34–5 (in Russian).
58. Egorov A.E. Controlled local inflammation as a new approach to the treatment of glaucoma optic neuropathy. Moscow; 2003 (in Russian).
59. Gil'manshin T.R., Fayzrakhmanov R.R., Arslangareeva I.I., et al. Local ways of drug administration in ophthalmology: advantages and disadvantages (literature review). Point of view. East-West. 2016; 3: 165–8 (in Russian).
60. Morgan C.M., Schatz H., Vine A.K., et al. Ocular complications associated with retrobulbar injections. Ophthalmology. 1988; 95 (5): 660–5.
61. Mikhailov A.I., Kocherovets V.I., Mar'yanovskii A.A. The capacity of gentamycini to penetrate to the site of infected injure of intraocular membranes depending on the route of the antibiotic administration. Vestnik oftal’mologii. 1979; 5: 38–4 (in Russian).
62. Magaramov D.A., Shmykova P.A., Latypov I.A. Medicinal agent deliverer to posterior pole of the eyeball and related method of medicinal agents’ delivery to posterior pole of the eyeball. Patent RF № 2327437; 2008 (in Russian).
63. Egorov E.A., Gvetadze A.A., Davydova N.G. Antioxidant drug in neuroprotective therapy for glaucoma. Vestnik oftal’mologii. 2013; 2: 67–9 (in Russian).
64. Egorov E.A., Obruch B.V., Oleinik A.I., et al. Usage of Mexidol in patients with dystrophic diseases of posterior eye segment. Klinicheskaja oftal’mologija. 2009; 10 (4): 145–8 (in Russian).
65. Mashkovskii M.D. Medicinal products. Moscow: Novaya Volna; 2002 (in Russian).
66. Maus T.L., Larsson L.I., McLaren J.W., Brubaker R.F. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. 1997; 115 (1): 45–9.
67. Makashova N.V., Parkanskaya V.I., Ronzina I.A., et al. Multifunctional drugs in complex treatment of optic neuropathy. Glaucoma. 2010; 9 (4): 32–4 (in Russian).
68. Verigo E.N., Zinoviev M.Yu., Poliakova L.Ya. Ophthalmohypertension in post-contusion hyphema. Glaucoma. 2003; 4: 45–50 (in Russian).
69. Vodovozov A.M. Concentration of penicillin in the conjunctival sac when applied to a colloidal capsule. Oftal’mologicheskij zhurnal. Ukraine. 1958; 5: 308–9 (in Russian).
70. Pollack I.P., Quigley H.A., Harbin T.S.The Ocusert pilocarpine system: advantages and disadvantages. South Med J. 1976; 69 (10): 1296–8.
71. Malanova N.L., Murzin A.A., Kanygina E.L., et al. Medicinal films with fibrinolysin in ophthalmology. Vestnik oftal’mologii. 1979; 3: 58–9 (in Russian).
72. Maychuk Yu.F. Ocular medicinal films: problems and prospects. Vestnik oftal’mologii. 1991; 5: 54–8 (in Russian).
73. Azamatova G.A., Aznabaev M.T., Monakov Yu.B., et al. Eye medicinal film. Patent RF № 2404779; 2010 (in Russian).
74. Erichev V.P., Maichuk Yu.F. Eye medicinal films with pilocarpine in the treatment of glaucoma. Methodical recommendations. Moscow; 1981 (in Russian).
75. VolkovV.V., BrzheskyV.V., UshakovN.A. Sankt-Petersburg: Hippokrat; 2003 (in Russian).
76. Grusha O.V., Ivanova L.A., Popova Z.S. Experimental study of intraocular medicinal films with Dexamethasone and Canamicyn based on collagen. Vestnik oftal’mologii. 1984; 5: 51–3 (in Russian).
77. Gendrolis A.Yu. Eye medicinal forms in pharmacy. Moscow: Meditsina; 1988 (in Russian).
78. Khatminskii Yu.F., Basova G.G. Physico-chemical assessment of the effectiveness of the ion exchange inserts in the treatment of alkaline burns of the eye. Oftal’mologicheskij zhurnal. 1992; 1: 44–6 (in Russian).
79. Ochirova E.K., Plekhanov A.N. Medical treatment of eye burns (literature review). Bulletin VCNC SO RAMS. 2010; 3 (73): 364–9 (in Russian).
80. Danilichev V.F. Pathology of the eye. Enzymes and inhibitors. SanktPeterburg: Stroilespechat'; 1996 (in Russian).
Review
For citations:
Kuroyedov A.V., Brzhesky V.V., Krinitsyna E.A. Traditional, unfairly forgotten, rarely used and promising drug delivery methods in ophthalmology: a clinical interpretation (part 1). Russian Ophthalmological Journal. 2019;12(2):83-95. (In Russ.) https://doi.org/10.21516/2072-0076-2019-12-2-83-95
Views:
1652
Email this article 